SCHEMBL16370332

SCHEMBL16370332

CCOC(=O)C1(c2nnc(-c3nn(COCC[Si](C)(C)C)c4nc(C)ccc34)nc2Cl)CC1

nearest known ligand 0.38

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ PDE5A O76074 12/20 0.38
▸ DGAT1 O75907 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17766175 0.91 PDE5A (0.38) PDE5ADGAT1
SCHEMBL18671456 0.90 PDE5A (0.37) PDE5A
SCHEMBL18671468 0.81 PDE5A (0.38) PDE5A
SCHEMBL16370351 0.77 PDE5A (0.62) PDE5A
SCHEMBL16370484 0.76 DGAT1 (0.39) PDE5ADGAT1
SCHEMBL16370265 0.74 PDE5A (0.63) PDE5A
SCHEMBL16370405 0.72 DGAT1 (0.33) PDE5ADGAT1
SCHEMBL16370404 0.70 DGAT1 (0.39) PDE5ADGAT1
SCHEMBL16370409 0.70 PDE5A (0.48) PDE5A
SCHEMBL18671448 0.66 PDE5A (0.61) PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9605008-B2 Benzyl-1H-pyrazolo[3,4-b]pyridines and use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-03-28 — — US disclosed
US-9605008-B2 Benzyl-1H-pyrazolo[3,4-b]pyridines and use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-03-28 — — US disclosed
US-9605008-B2 Benzyl-1H-pyrazolo[3,4-b]pyridines and use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-03-28 — — US disclosed
US-20160145271-A1 BENZYL-1H-PYRAZOLO[3,4-B]PYRIDINES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-05-26 — — US disclosed
US-20160145271-A1 BENZYL-1H-PYRAZOLO[3,4-B]PYRIDINES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-05-26 — — US disclosed
US-20160145271-A1 BENZYL-1H-PYRAZOLO[3,4-B]PYRIDINES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-05-26 — — US disclosed
EP-3019506-A1 BENZYL-1H-PYRAZOLO[3,4-B]PYRIDINES AND USE THEREOF Bayer Pharma Aktiengesellschaft (DE) 2016-05-18 — — EP disclosed
WO-2015004105-A1 BENZYL-1H-PYRAZOLO[3,4-B]PYRIDINES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-01-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145271-A1 BENZYL-1H-PYRAZOLO[3,4-B]PYRIDINES AND USE THEREOF PNPO, PLPBP, CYP4B1 PDE5A 439/4885DGAT1 4591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback